CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Repaglinide

瑞格列奈 杂质对照品Repaglinide Impurities

EPUSP33 个杂质条目33 impurity entries

本页汇总 瑞格列奈 的 33 个杂质对照品条目,其中药典杂质标注了 EP/USP 编号。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 33 impurity reference standards of Repaglinide with EP/USP numbering where applicable. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 瑞格列奈(Repaglinide)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesSimultaneous Determination of Metformin, Glipizide, Repaglinide, and Glimepiride or Metformin and Pioglitazone by a Validated LC Method: Application in the Presence of Metformin Impurity (1-Cyanoguanidine)
    Journal of AOAC International · 2016 · El-Zaher AA et al.  ·  PMID 27214744  ·  DOI
  2. 杂质研究Impurity studiesIdentification, isolation, and synthesis of seven novel impurities of anti-diabetic drug Repaglinide
    Drug testing and analysis · 2018 · Kancherla P et al.  ·  PMID 28421713  ·  DOI
  3. 杂质研究Impurity studiesLiquid chromatography/electrospray ionization tandem mass spectrometry study of repaglinide and its forced degradation products
    Rapid communications in mass spectrometry : RCM · 2018 · Purna Chander C et al.  ·  PMID 29723439  ·  DOI
  4. 分析方法Analytical MethodsSimultaneous estimation of six anti-diabetic drugs--glibenclamide, gliclazide, glipizide, pioglitazone, repaglinide and rosiglitazone: development of a novel HPLC method for use in the analysis of pharmaceutical formulations and its application to human plasma assay
    Biomedical chromatography : BMC · 2006 · Venkatesh P et al.  ·  PMID 16506282  ·  DOI
  5. 分析方法Analytical MethodsDoE-assisted HPLC method development and validation of enzalutamide and repaglinide in rat plasma
    Bioanalysis · 2024 · Reddy GN et al.  ·  PMID 39115061  ·  DOI

瑞格列奈 —— 原料药与杂质对照品Repaglinide — drug substance & impurities

共 34 个条目(含原料药本体)34 items incl. the drug substance
Repaglinide structure
EP原料药 APIAPI
瑞格列奈Repaglinide
Repaglinide
CAS No.135062-02-1
Chemical FormulaC27H36N2O4
Purity>95%现货In stock
10mg25mg50mg100mg
Repaglinide Impurity 1(Repaglinide EP Impurity A) structure
EPA
瑞格列奈杂质1(瑞格列奈EP杂质A)Repaglinide Impurity 1(Repaglinide EP Impurity A)
Repaglinide Impurity 1(Repaglinide EP Impurity A)
CAS No.220438-80-2
Chemical FormulaC11H12O5
Purity>95%询价On request
10mg25mg50mg100mg
Repaglinide Impurity 2 CRS (Repaglinide EP Impurity B CRS) structure
EPB
瑞格列奈杂质2 CRS (瑞格列奈EP杂质B CRS)Repaglinide Impurity 2 CRS (Repaglinide EP Impurity B CRS)
Repaglinide Impurity 2 CRS (Repaglinide EP Impurity B CRS)
CAS No.99469-99-5
Chemical FormulaC13H16O5
Purity>95%询价On request
10mg25mg50mg100mg
Repaglinide Impurity 3 (Repaglinide EP Impurity C) structure
EPC
瑞格列奈杂质3 (瑞格列奈EP杂质C)Repaglinide Impurity 3 (Repaglinide EP Impurity C)
Repaglinide Impurity 3 (Repaglinide EP Impurity C)
CAS No.147769-93-5
Chemical FormulaC16H26N2
Purity>95%询价On request
10mg25mg50mg100mg
Repaglinide Impurity 3 N-Acetyl-L-glutamate Salt (Repaglinide EP Impurity C N-Acetyl-L-glutamate Salt) structure
EPC
瑞格列奈杂质3 N-乙酰基-L-谷氨酸盐 (瑞格列奈EP杂质C N-乙酰基-L-谷氨酸盐)Repaglinide Impurity 3 N-Acetyl-L-glutamate Salt (Repaglinide EP Impurity C N-Acetyl-L-glutamate Salt)
Repaglinide Impurity 3 N-Acetyl-L-glutamate Salt (Repaglinide EP Impurity C N-Acetyl-L-glutamate Salt)
CAS No.219921-94-5
Chemical FormulaC16H26N2·C7H11NO5
Purity>95%询价On request
10mg25mg50mg100mg
Repaglinide Impurity 4(Repaglinide EP Impurity D) structure
EPD
瑞格列奈杂质4(瑞格列奈EP杂质D)Repaglinide Impurity 4(Repaglinide EP Impurity D)
Repaglinide Impurity 4(Repaglinide EP Impurity D)
CAS No.147770-06-7
Chemical FormulaC29H40N2O4
Purity>95%询价On request
10mg25mg50mg100mg
Repaglinide Impurity 5(Repaglinide EP Impurity E) structure
EPE
瑞格列奈杂质5(瑞格列奈EP杂质E)Repaglinide Impurity 5(Repaglinide EP Impurity E)
Repaglinide Impurity 5(Repaglinide EP Impurity E)
CAS No.147852-26-4
Chemical FormulaC27H36N2O4
Purity>95%询价On request
10mg25mg50mg100mg
Repaglinide Impurity 6 (Repaglinide USP Related Compound C) structure
USPC
瑞格列奈杂质6 (瑞格列奈USP相关化合物C)Repaglinide Impurity 6 (Repaglinide USP Related Compound C)
Repaglinide Impurity 6 (Repaglinide USP Related Compound C)
CAS No.1803084-79-8
Chemical FormulaC30H34N2O4
Purity>95%询价On request
10mg25mg50mg100mg
Repaglinide Impurity O structure
O
瑞格列奈杂质ORepaglinide Impurity O
Repaglinide Impurity O
CAS No.147770-03-4
Chemical FormulaC16H23NO
Purity>95%现货In stock
10mg25mg50mg100mg
Repaglinide Impurity 8 structure
8
瑞格列奈杂质8Repaglinide Impurity 8
Repaglinide Impurity 8
CAS No.147770-08-9
Chemical FormulaC29H40N2O4
Purity>95%询价On request
10mg25mg50mg100mg
Repaglinide Impurity 9 structure
9
瑞格列奈杂质9Repaglinide Impurity 9
Repaglinide Impurity 9
CAS No.2519482-34-7
Chemical FormulaC27H34N2O4
Purity>95%询价On request
10mg25mg50mg100mg
Repaglinide Impurity 10 structure
10
瑞格列奈杂质10Repaglinide Impurity 10
Repaglinide Impurity 10
CAS No.2519482-33-6
Chemical FormulaC27H34N2O4
Purity>95%询价On request
10mg25mg50mg100mg
Repaglinide Impurity 15 structure
15
瑞格列奈杂质15Repaglinide Impurity 15
Repaglinide Impurity 15
CAS No.88709-17-5
Chemical FormulaC12H16O3
Purity>95%询价On request
10mg25mg50mg100mg
Repaglinide Impurity 16 structure
16
瑞格列奈杂质16Repaglinide Impurity 16
Repaglinide Impurity 16
CAS No.110017-07-7
Chemical FormulaC12H15BrO3
Purity>95%询价On request
10mg25mg50mg100mg
Repaglinide Impurity 21 structure
21
瑞格列奈杂质21Repaglinide Impurity 21
Repaglinide Impurity 21
CAS No.60770-00-5
Chemical FormulaC10H12O3
Purity>95%询价On request
10mg25mg50mg100mg
Repaglinide Impurity 24 Monomer structure
24
瑞格列奈杂质24 单体Repaglinide Impurity 24 Monomer
Repaglinide Impurity 24 Monomer
CAS No.108157-52-4
Chemical FormulaC16H26N2
Purity>95%询价On request
10mg25mg50mg100mg
Repaglinide Impurity 24 structure
24
瑞格列奈杂质24Repaglinide Impurity 24
Repaglinide Impurity 24
CAS No.1221593-85-6
Chemical FormulaC16H26N2·C5H8O4
Purity>95%询价On request
10mg25mg50mg100mg
Repaglinide Impurity 24 Adipate Salt structure
24
瑞格列奈杂质24 己二酸盐Repaglinide Impurity 24 Adipate Salt
Repaglinide Impurity 24 Adipate Salt
CAS No.1262393-01-0
Chemical FormulaC16H26N2·C6H10O4
Purity>95%询价On request
10mg25mg50mg100mg
Repaglinide Impurity 30 structure
30
瑞格列奈杂质30Repaglinide Impurity 30
Repaglinide Impurity 30
CAS No.2519482-22-3
Chemical FormulaC27H34N2O4
Purity>95%询价On request
10mg25mg50mg100mg
Repaglinide Impurity 31 structure
31
瑞格列奈杂质31Repaglinide Impurity 31
Repaglinide Impurity 31
CAS No.2030678-00-1
Chemical FormulaC13H16O5
Purity>95%询价On request
10mg25mg50mg100mg
Repaglinide Impurity 33 structure
33
瑞格列奈杂质33Repaglinide Impurity 33
Repaglinide Impurity 33
CAS No.1549710-21-5
Chemical FormulaC16H26N2
Purity>95%询价On request
10mg25mg50mg100mg
Repaglinide Impurity 34 structure
34
瑞格列奈杂质34Repaglinide Impurity 34
Repaglinide Impurity 34
CAS No.219921-93-4
Chemical FormulaC16H26N2
Purity>95%询价On request
10mg25mg50mg100mg
Repaglinide Impurity 35 structure
35
瑞格列奈杂质35Repaglinide Impurity 35
Repaglinide Impurity 35
CAS No.72752-52-4
Chemical FormulaC12H14N2
Purity>95%询价On request
10mg25mg50mg100mg
Repaglinide Impurity 36 structure
36
瑞格列奈杂质36Repaglinide Impurity 36
Repaglinide Impurity 36
CAS No.2519482-21-2
Chemical FormulaC25H32N2O4
Purity>95%询价On request
10mg25mg50mg100mg
Repaglinide Impurity 38 structure
38
瑞格列奈杂质38Repaglinide Impurity 38
Repaglinide Impurity 38
CAS No.121167-81-5
Chemical FormulaC27H36N2O5
Purity>95%询价On request
10mg25mg50mg100mg
Repaglinide Impurity 39 structure
39
瑞格列奈杂质39Repaglinide Impurity 39
Repaglinide Impurity 39
CAS No.2375485-04-2
Chemical FormulaC26H36N2O3
Purity>95%询价On request
10mg25mg50mg100mg
Repaglinide Impurity 41 structure
41
瑞格列奈杂质41Repaglinide Impurity 41
Repaglinide Impurity 41
CAS No.1336666-36-4
Chemical FormulaC16H26N2
Purity>95%询价On request
10mg25mg50mg100mg
Repaglinide Impurity 45 structure
45
瑞格列奈杂质45Repaglinide Impurity 45
Repaglinide Impurity 45
CAS No.637301-29-2
Chemical FormulaC22H28N2O4
Purity>95%询价On request
10mg25mg50mg100mg
Repaglinide Impurity 46 structure
46
瑞格列奈杂质46Repaglinide Impurity 46
Repaglinide Impurity 46
CAS No.874908-11-9
Chemical FormulaC22H28N2O4
Purity>95%询价On request
10mg25mg50mg100mg
Repaglinide Impurity 52 structure
52
瑞格列奈杂质52Repaglinide Impurity 52
Repaglinide Impurity 52
CAS No.332347-70-3
Chemical FormulaC16H25NO
Purity>95%询价On request
10mg25mg50mg100mg
Repaglinide Impurity 53 structure
53
瑞格列奈杂质53Repaglinide Impurity 53
Repaglinide Impurity 53
CAS No.1956316-97-4
Chemical FormulaC17H28N2
Purity>95%询价On request
10mg25mg50mg100mg
Repaglinide Impurity 54 structure
54
瑞格列奈杂质54Repaglinide Impurity 54
Repaglinide Impurity 54
CAS No.791812-92-5
Chemical FormulaC26H34N2O4
Purity>95%询价On request
10mg25mg50mg100mg
Repaglinide Impurity 55 (Repaglinide Acyl-β-D-glucuronide) structure
55
瑞格列奈杂质55 (瑞格列奈酰基-β-D-葡萄糖醛酸苷)Repaglinide Impurity 55 (Repaglinide Acyl-β-D-glucuronide)
Repaglinide Impurity 55 (Repaglinide Acyl-β-D-glucuronide)
CAS No.1309112-13-7
Chemical FormulaC33H44N2O10
Purity>95%询价On request
10mg25mg50mg100mg
Repaglinide Impurity 54-11C structure
54-11C
瑞格列奈杂质54-11CRepaglinide Impurity 54-11C
Repaglinide Impurity 54-11C
CAS No.791812-93-6
Chemical FormulaC2511CH34N2O4
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

瑞格列奈 —— 研究文献与合成路线Repaglinide — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 瑞格列奈 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Repaglinide. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Liquid chromatography/electrospray ionization tandem mass spectrometry study of repaglinide and its forced degradation products
    Purna Chander C, Raju B, Ramesh M, et al. · Rapid communications in mass spectrometry : RCM · 2018 · 被引 3cited 3
  2. Simultaneous Determination of Metformin, Glipizide, Repaglinide, and Glimepiride or Metformin and Pioglitazone by a Validated LC Method: Application in the Presence of Metformin Impurity (1-Cyanoguanidine)
    El-Zaher AA, Elkady EF, Elwy HM, et al. · Journal of AOAC International · 2016 · 被引 8cited 8
  3. Identification, isolation, and synthesis of seven novel impurities of anti-diabetic drug Repaglinide
    Kancherla P, Keesari S, Alegete P, et al. · Drug testing and analysis · 2018 · 被引 2cited 2
  4. Impurity profile study of repaglinide
    Reddy KV, Babu JM, Mathad VT, et al. · Journal of pharmaceutical and biomedical analysis · 2003 · 被引 4cited 4
  5. Repaglinide Substantially Free of Dimer Impurity
    SEBASTIAN SONNY, BALLA SASIDHAR VENKATA, KATIKAREDDY RAMAMURTHY, et al. · 2010
  6. Stability-indicating assay of repaglinide in bulk and optimized nanoemulsion by validated high performance thin layer chromatography technique
    Akhtar J, Fareed S, Aqil M · Journal of pharmacy & bioallied sciences · 2013 · 被引 2cited 2

合成与制备工艺专利Synthesis & process patents

  1. PROCESS FOR PREPARING REPAGLINIDE INTERMEDIATE
    XIAO JUN, KONG SHUANGHUA, LUE AIFENG · 公开号 WO2009114987WO2009114987 · 2009
  2. MOTHED FOR PREPARING REPAGLINIDE
    LUE AIFENG, KONG SHUANGHUA, XIAO JUN, CHEN GANGSHENG · 公开号 WO2009086728WO2009086728 · 2009
  3. Process for the preparation of substantially optically pure repaglinide and precursors thereof
    VEVERKA MIROSLAV, VEVERKOVA EVA, KLVANOVA JANA, BOMBEK SERGEJA, et al. · 公开号 EP2358369EP2358369 · 2011
  4. Repaglinide synthesis process
    YANG JIAN XU · 公开号 CN1865253CN1865253 · 2006
  5. PROCESS FOR THE PREPARATION OF SUBSTANTIALLY OPTICALLY PURE REPAGLINIDE AND PRECURSORS THEREOF
    VEVERKA MIROSLAV, VEVERKOVA EVA, KLVANOVA JANA, BOMBEK SERGEJA, et al. · 公开号 WO2010046360WO2010046360 · 2010

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

瑞格列奈 杂质谱研究要点Repaglinide — impurity profiling notes

下面这些是拿到 瑞格列奈 的 34 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 34 impurity entries for Repaglinide, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

本品种含药典编号杂质(EP/USP)。申报时药典已收载的杂质通常需要逐项对照,建议优先备齐药典编号对照品,再补充工艺与降解杂质。This drug substance includes pharmacopoeially designated impurities (EP/USP). Monographed impurities normally need item-by-item comparison during filing, so secure the pharmacopoeial standards first, then fill in process and degradation impurities.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances